COMPANY PROFILE

CUBEBIO 　

Explore full profile

A biomedical company specializing in early cancer detection through self-diagnosis using urine samples

Seoul, South KoreaFounded 2011Biotech & Life Sciences

Valuation $500M–1B Last recorded · 2024

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

At a glance

Status: Operational
Founded: 2011
Headquarters: Seoul, South Korea
Employees: 16
Open positions: None listed
Dealroom signal: 41.1/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SPAC IPOOther financing	May 2024	$69M	$620M	Mountain Crest Acquisition Corp. V	↗
SEEDOther financing	Sep 2023	$52M	$208M	Undisclosed	↗

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

CUBEBIO 　 website traffic

Latest recorded traffic for CUBEBIO 　 is 850 monthly website visits, down 85.3% over the last three months. CUBEBIO 　's team grew 14.3% over the past year.

Latest monthly visits850 3-month web change-85.3% 1-year team growth+14.3%

Monthly website visitsApr 2024–Jun 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ANAntegenesGenetic tests for personalized cancer risk prevention	Tartu, Estonia	Operational	11	$3.4M	$7M
FEFemtogenixDNA-interactive payloads for antibody-drug conjugates	St Albans, United Kingdom	Operational
ETEpics TherapeuticsDrug discovery and development company that invents and develops small molecule drugs targeting RNA epigenetic mechanisms involved in cancer development	Charleroi, Belgium	Operational
IAIOmx Therapeutics AGDeveloping next-generation targeted cancer immunotherapy treatments	Planegg, Germany	Operational
TBTILT BiotherapeuticsTILT Bio aims to enable T-cell treatments and immune checkpoint inhibitors with oncolytic viruses, used to boost lymphocytes and immunological checkpoint blocking antibody treatments	Helsinki, Finland	Operational
PGPhase GenomicsPhase Genomics' mission is to help scientists make breakthrough discoveries by providing the most complete, accurate, detailed genomes	Seattle, United States	Operational
THTheraBiologicsA proprietary human nsc platform for cancer treatment	United States	Operational
ABAkamis BioLeading company in developing cancer gene therapies	Abingdon, United Kingdom	Operational